Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Leukemia

  Free Subscription


12.02.2024

4 Am J Hematol
4 Ann Hematol
4 Blood
2 Bone Marrow Transplant
12 Br J Haematol
1 Cancer
1 Eur J Haematol
1 Exp Hematol
1 Genomics
1 J Pediatr Hematol Oncol
2 Leuk Lymphoma
10 Leukemia


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. CHEN X, Yuan L, Zhang Y, Wang F, et al
    Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
    Am J Hematol. 2024 Feb 6. doi: 10.1002/ajh.27249.
    PubMed         Abstract available

  2. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
    Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
    PubMed         Abstract available

  3. HORNAK T, Mayer J, Cicatkova P, Semerad L, et al
    De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27229.
    PubMed         Abstract available

  4. BENESOVA A, De Santis S, Polivkova V, Pecherkova P, et al
    Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
    Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27232.
    PubMed        


    Ann Hematol

  5. ZHAO L, Yang J, Chen M, Xiang X, et al
    Myelomonocytic and monocytic acute myeloid leukemia demonstrate comparable poor outcomes with venetoclax-based treatment: a monocentric real-world study.
    Ann Hematol. 2024 Feb 8. doi: 10.1007/s00277-024-05646.
    PubMed         Abstract available

  6. FONTANA D, Zambrotta GPM, Scannella A, Piazza R, et al
    Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
    Ann Hematol. 2024 Feb 7. doi: 10.1007/s00277-024-05649.
    PubMed         Abstract available

  7. SCHLOSSER P, Schiwitza A, Klaus J, Hieke-Schulz S, et al
    Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05627.
    PubMed         Abstract available

  8. SUAREZ EU, Piris MA, Rodriguez-Pinilla SM, Garcia JF, et al
    Progression of myeloproliferative neoplasm with BCR::JAK2 fusion to acute leukemia of ambiguous lineage.
    Ann Hematol. 2024 Feb 3. doi: 10.1007/s00277-024-05647.
    PubMed        


    Blood

  9. BHATT VR, Uy GL, Klepin HD
    Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action.
    Blood. 2024;143:483-487.
    PubMed         Abstract available

  10. DAO T, Xiong G, Mun SS, Meyerberg J, et al
    A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
    Blood. 2024;143:507-521.
    PubMed         Abstract available

  11. QIU L, Naresh KN
    Mature plasmacytoid dendritic cell proliferation in association with mixed-phenotype acute leukemia, T/myeloid.
    Blood. 2024;143:561.
    PubMed        

  12. ARBER C
    Two to tango: engineered T cells against AML.
    Blood. 2024;143:476-478.
    PubMed        


    Bone Marrow Transplant

  13. YANADA M, Yano S, Kuwatsuka Y, Kawamura K, et al
    The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia.
    Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02222.
    PubMed         Abstract available

  14. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    PubMed         Abstract available


    Br J Haematol

  15. BAI L, Zhang ZX, Hu GH, Cheng YF, et al
    Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
    Br J Haematol. 2024;204:585-594.
    PubMed         Abstract available

  16. SHEN Y, Freeman JA, Kerridge I, Downe P, et al
    Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
    Br J Haematol. 2024;204:487-491.
    PubMed         Abstract available

  17. MARK C, Meshinchi S, Joyce B, Gibson B, et al
    Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
    Br J Haematol. 2024;204:576-584.
    PubMed         Abstract available

  18. MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
    The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
    PubMed         Abstract available

  19. RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
    Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
    Br J Haematol. 2024;204:595-605.
    PubMed         Abstract available

  20. NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
    Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
    Br J Haematol. 2024;204:719-723.
    PubMed        

  21. NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
    Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
    Br J Haematol. 2024;204:724-729.
    PubMed        

  22. KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
    Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
    Br J Haematol. 2024;204:561-565.
    PubMed         Abstract available

  23. WANG Z, Fan Z, Wu Z, Xuan L, et al
    PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
    Br J Haematol. 2024;204:628-637.
    PubMed         Abstract available

  24. FUJI S, Yuda S, Tada Y, Kano M, et al
    A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
    Br J Haematol. 2024;204:e25-e27.
    PubMed        

  25. PARDANANI A, Reichard K, Tefferi A
    Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
    Br J Haematol. 2024;204:402-414.
    PubMed         Abstract available

  26. COSTA A, Breccia M
    How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
    Br J Haematol. 2024;204:434-448.
    PubMed         Abstract available


    Cancer

  27. GUAN F, Yang L, Chen Y, Shi J, et al
    Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
    Cancer. 2024 Feb 5. doi: 10.1002/cncr.35232.
    PubMed         Abstract available


    Eur J Haematol

  28. MELLINGHOFF SC, Robrecht S, Sprute R, Mayer L, et al
    Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
    Eur J Haematol. 2024 Feb 4. doi: 10.1111/ejh.14170.
    PubMed         Abstract available


    Exp Hematol

  29. RANDALL J, Evans K, Watts B, Kosasih HJ, et al
    IN VIVO ACTIVITY OF THE SECOND-GENERATION PROTEASOME INHIBITOR IXAZOMIB AGAINST PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS.
    Exp Hematol. 2024 Feb 4:104176. doi: 10.1016/j.exphem.2024.104176.
    PubMed         Abstract available


    Genomics

  30. JIANG L, Hong H, Xiang S, Li H, et al
    Integrated gene co-expression network analysis and experimental validation revealed potential targets of human urine extract CDA-II in treating chronic myeloid leukemia.
    Genomics. 2024 Feb 5:110806. doi: 10.1016/j.ygeno.2024.110806.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  31. DU Y, Yang L, Qi S, Chen Z, et al
    Clinical Analysis of Pediatric Acute Megakaryocytic Leukemia With CBFA2T3-GLIS2 Fusion Gene.
    J Pediatr Hematol Oncol. 2024 Feb 1. doi: 10.1097/MPH.0000000000002822.
    PubMed         Abstract available


    Leuk Lymphoma

  32. YARED JA, Lee TY, Cooke CE, Johnson A, et al
    Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors.
    Leuk Lymphoma. 2024 Feb 7:1-11. doi: 10.1080/10428194.2024.2310150.
    PubMed         Abstract available

  33. TANG K, Lipton JH
    Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
    Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
    PubMed         Abstract available


    Leukemia

  34. LI Y, Mendoza-Castrejon J, Patel RM, Casey EB, et al
    LIN28B promotes differentiation of fully transformed AML cells but is dispensable for fetal leukemia suppression.
    Leukemia. 2024 Feb 6. doi: 10.1038/s41375-024-02167.
    PubMed        

  35. KLYUCHNIKOV E, Badbaran A, Massoud R, Freiberger P, et al
    Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR.
    Leukemia. 2024;38:386-388.
    PubMed        

  36. ELDEEB M, Konturek-Ciesla A, Zhang Q, Kharazi S, et al
    Ontogeny shapes the ability of ETV6::RUNX1 to enhance hematopoietic stem cell self-renewal and disrupt early lymphopoiesis.
    Leukemia. 2024;38:455-459.
    PubMed        

  37. GEORGI JA, Stasik S, Kramer M, Meggendorfer M, et al
    Prognostic impact of CEBPA mutational subgroups in adult AML.
    Leukemia. 2024;38:281-290.
    PubMed         Abstract available

  38. HEHLMANN R, Lauseker M
    How to individualize therapy after failing milestones in chronic myeloid leukaemia: weighting late response and early death from CML against risk of alternative therapies.
    Leukemia. 2024;38:465-466.
    PubMed        

  39. CHEN J, Gale RP
    Response to Pfirrmann et al.'s comment on How should we interpret conclusions of TKI-stopping studies.
    Leukemia. 2024;38:463-464.
    PubMed        

  40. LEE KH, Lee S, Park YH, Mun YC, et al
    Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis.
    Leukemia. 2024;38:451-454.
    PubMed        

  41. MATTANO LA JR, Devidas M, Loh ML, Raetz EA, et al
    Development of osteonecrosis and improved survival in B-ALL: results of Children's Oncology Group Trial AALL0232.
    Leukemia. 2024;38:258-265.
    PubMed         Abstract available

  42. CHEN Y, Wen J, Li Q, Peng D, et al
    RAB27B-regulated exosomes mediate LSC maintenance via resistance to senescence and crosstalk with the microenvironment.
    Leukemia. 2024;38:266-280.
    PubMed         Abstract available

  43. SUI P, Ge G, Chen S, Bai J, et al
    SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis.
    Leukemia. 2024;38:408-411.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.